MR. JOSEPH DANIEL ELFERT JR. MD LLC
Prescription History 1790745073
Pediatrics in Crowley, LA

NPI Status: Active since March 23, 2006

Contact Information

1325 WRIGHT AVE
STE F
CROWLEY, LA
ZIP 70526
Phone: (337) 783-2915
Fax: (337) 783-2704

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. JOSEPH DANIEL ELFERT JR. MD LLC, an active Pediatrics specialist practicing in Crowley, LA. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 11 documented patient claims. Among these therapy options, the most frequently utilized medication is Amlodipine-Olmesartan, which accounts for 11 claims alone.

Medication Index

No matching medications currently found on file.

Amlodipine-Olmesartan

Generic Formulation: Amlodipine Bes/Olmesartan MedSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
LA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills43.4
Peer Average Days Supply1,295
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $96.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.81

State Avg Cost Per Claim

$69.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A sulfonic acid-based naphthylazo dye used as a coloring agent for foodstuffs and medicines and as a dye and chemical indicator. It was banned by the FDA in 1976 for use in foods, drugs, and cosmetics. (From Merck Index, 11th ed)

Therapeutic Applications

This product is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This product contains 2 medications: amlodipine and olmesartan. They both work by relaxing blood vessels so blood can flow more easily. Amlodipine is a calcium channel blocker and olmesartan is an angiotensin receptor blocker (ARB).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MR. JOSEPH DANIEL ELFERT JR. MD LLC provides transparency into local medical care patterns within Crowley, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pediatrics** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.